ARS Pharmaceuticals, Inc. (SPRY) Fair Value 2026 — DCF & Multi-Method Analysis | EvidInvest | EvidInvest

SPRY — Fair Value Analysis

ARS Pharmaceuticals, Inc.

Current: $6.24

⚠

High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.

Fair Value Range

Bear Case (25th pct.)

$144.88

2221.8% vs price

Base Case (Median)

$144.88

2221.8% vs price

Bull Case (75th pct.)

$144.88

2221.8% vs price

Method Breakdown

Method	Est. Value	vs Price	Weight
DCF (Discounted Cash Flow)	$144.88	2221.8%	High (40%)

Interpretation

Insufficient data to generate a reliable fair value estimate for SPRY. Try again later or check if this symbol has full financial data.

Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.